Preliminary survey of the threatened carnivores in the Daraina Loky-Manambato Protected Area, Madagascar

Madagascar’s protected areas safeguard numerous threatened endemic plant and animal species, including Euplerid carnivores, considered to be the most threatened yet understudied group of carnivores globally. The Loky-Manambato Protected Area (PA) in northern Madagascar encompasses a unique transitional forest ecosystem that is under pressure from forest loss and fragmentation. We provide the first photographic survey of Madagascar’s carnivore community occupying this region with the aim of documenting carnivore species richness, relative activity (Trap Success), and spatial distribution (Naïve occupancy) across the landscape. To do this, we used 60 motion-activated cameras to survey along established trails in three forest patches across the Loky-Manambato PA: Antsahabe, Bekaraoka, and Antsaharaingy. We surveyed each forest for two weeks in September and October 2018. We collected 498 independent captures of fauna across the landscape, including five of the six endemic carnivores known to occupy eastern Madagascar: Galidia elegans, Galidictis fasciata, Eupleres goudotii, Fossa fossana, and Cryptoprocta ferox. We found F. fossana and G. elegans to be the most active and widely distributed carnivores, while C. ferox, G. fasciata and E. goudotii were the least. Additionally, we documented the presence of two invasive carnivores: Canis familiaris and Felis catus. These findings extended the northern-most known range of Galidictis fasciata (Antsahabe) and Fossa fossana (Bekaraoka) into the Loky-Manambato PA. Forest size was not a good predictor of activity or occurrence as the largest forest patch in Bekaraoka had the fewest captures of all carnivores. Our findings highlight some of the biodiversity within the Loky-Manambato PA and the need for effective management across this unique transitional forest ecosystem.  RÉSUMÉLes aires protégées de Madagascar protègent de nombreuses espèces végétales et animales endémiques menacées, y compris les carnivores eupléridés. Les carnivores eupléridés sont considérés comme l'un des groupes de carnivores les plus menacés mais les moins étudiés au monde. L'aire protégée (PA) de Loky- Manambato dans le nord de Madagascar englobe un écosystème forestier de transition unique qui subit la pression de la perte et de la fragmentation des forêts. Nous fournissons la première étude photographique de la communauté de carnivores de Madagascar occupant cette région dans le but de documenter la richesse en espèces de carnivores, l'activité relative (Trap Success) et la distribution spatiale (Naïve occupancy) à travers le paysage. Pour ce faire, nous avons utilisé 60 caméras activées par le mouvement pour surveiller le long des sentiers établis dans trois parcelles forestières à travers l’AP Loky-Manambato : Antsahabe, Bekaraoka et Antsaharaingy. Nous avons étudié chaque forêt pendant deux semaines en septembre et octobre 2018. Nous avons procédé à 498 captures indépendantes de la faune à travers le paysage, incluant cinq des six carnivores endémiques connus pour habiter l'Est de Madagascar : Galidia elegans, Galidictis fasciata, Eupleres goudotii, Fossa fossana et Cryptoprocta ferox. Nous avons constaté que F. fossana et G. elegans étaient les carnivores les plus actifs et les plus largement distribués, tandis que C. ferox, G. fasciata et E. goudotii étaient les moins nombreux. De plus, nous avons documenté la présence de deux carnivores envahissants : Canis familiaris et Felis catus. Ces découvertes ont étendu l'aire de répartition la plus septentrionale connue de Galidictis fasciata (Antsahabe) et de Fossa fossana (Bekaraoka) dans l’AP Loky-Manambato. La taille de la forêt n'était pas un bon prédicteur de l'activité ou de l'occurrence car la plus grande parcelle forestière de Bekaraoka avait la moindre présence de tous les carnivores. Nos résultats mettent en évidence une partie de la biodiversité au sein de Loky-Manambato PA et la nécessité d'une gestion efficace dans cet écosystème forestier de transition uniqu

Shipping blood to a central laboratory in multicenter clinical trials: effect of ambient temperature on specimen temperature, and effects of temperature on mononuclear cell yield, viability and immunologic function

<p>Abstract</p> <p>Background</p> <p>Clinical trials of immunologic therapies provide opportunities to study the cellular and molecular effects of those therapies and may permit identification of biomarkers of response. When the trials are performed at multiple centers, transport and storage of clinical specimens become important variables that may affect lymphocyte viability and function in blood and tissue specimens. The effect of temperature during storage and shipment of peripheral blood on subsequent processing, recovery, and function of lymphocytes is understudied and represents the focus of this study.</p> <p>Methods</p> <p>Peripheral blood samples (n = 285) from patients enrolled in 2 clinical trials of a melanoma vaccine were shipped from clinical centers 250 or 1100 miles to a central laboratory at the sponsoring institution. The yield of peripheral blood mononuclear cells (PBMC) collected before and after cryostorage was correlated with temperatures encountered during shipment. Also, to simulate shipping of whole blood, heparinized blood from healthy donors was collected and stored at 15°C, 22°C, 30°C, or 40°C, for varied intervals before isolation of PBMC. Specimen integrity was assessed by measures of yield, recovery, viability, and function of isolated lymphocytes. Several packaging systems were also evaluated during simulated shipping for the ability to maintain the internal temperature in adverse temperatures over time.</p> <p>Results</p> <p>Blood specimen containers experienced temperatures during shipment ranging from -1 to 35°C. Exposure to temperatures above room temperature (22°C) resulted in greater yields of PBMC. Reduced cell recovery following cryo-preservation as well as decreased viability and immune function were observed in specimens exposed to 15°C or 40°C for greater than 8 hours when compared to storage at 22°C. There was a trend toward improved preservation of blood specimen integrity stored at 30°C prior to processing for all time points tested. Internal temperatures of blood shipping containers were maintained longer in an acceptable range when warm packs were included.</p> <p>Conclusions</p> <p>Blood packages shipped overnight by commercial carrier may encounter extreme seasonal temperatures. Therefore, considerations in the design of shipping containers should include protecting against extreme ambient temperature deviations and maintaining specimen temperature above 22°C or preferably near 30°C.</p

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p&lt;0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (&lt;1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (&lt;1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline

Madagascar Terrestrial Camera Survey Database 2021: A collation of protected forest camera surveys from 2007–2021

Madagascar is a threatened global biodiversity hotspot and conservation priority, yet we lack broad-scale surveys to assess biodiversity across space and time. To fill this gap, we collated camera trap surveys, capturing species occurrences within Madagascar into a single standardized database. This data set includes nine distinct protected areas of Madagascar and encompasses 13 subprojects, 38 camera arrays, and 1156 sampling units (independent camera site per survey) within two important biodiversity eco-regions: western dry deciduous forest and eastern humid rainforest. Camera surveys were conducted from June 2007 to January 2021. The final data set includes 17 unique families of mammals (Bovidae, Canidae, Cheirogaleidae, Daubentoniidae, Equidae, Eupleridae, Felidae, Hominidae, Indriidae, Lemuridae, Lepilemuridae, Muridae, Nesomyidae, Pteropodidae, Soricidae, Suidae, Tenrecidae) comprising 45 species and 27 unique families of birds (Accipitridae, Acrocephalidae, Alcedinidae, Bernieridae, Brachypteraciidae, Caprimulgidae, Cisticolidae, Columbidae, Coraciidae, Corvidae, Cuculidae, Dicruridae, Mesitornithidae, Monarchidae, Motacillidae, Muscicapidae, Numididae, Phasianidae, Rallidae, Sarothruridae, Strigidae, Sturnidae, Sulidae, Threskiornithidae, Upupidae, Vangidae, Zosteropidae) comprising 58 species. Images were processed and verified by individual project data set creators and camera operation and species tables were then collated. The final product represents the first broad-scale freely available standardized formal faunal database for Madagascar. Data are available through this publication and at DOI: 10.5281/zenodo.5801806. These data will be useful for examining species-level and community-level trends in occurrence across space or time within Madagascar and globally, evaluating native and invasive species dynamics, and will aid in determining species conservation status and planning for at-risk species. There are no copyright restrictions; please cite this paper when using the data for publication